Tag Archives: Therapy

No Major Benefits Of Plasma Therapy For Covid-19, New Study From India Finds

A healthcare worker collects swab samples from a woman at a testing site for COVID-19 in Mumbai, … [+] India on September 08, 2020. India is the second worst-hit nation by the Coronavirus (COVID-19) pandemic after the United States. (Photo by Himanshu Bhatt/NurPhoto via Getty Images) NurPhoto via Getty Images While the U.S. Food and… Read More »

Triple therapy helps control severe asthma

Asthma affects approximately 20 million adults in the US. It is a common cause of workplace and school absenteeism, and is one of the leading causes of hospitalizations in the US. Between 5% and 10% of asthmatics have frequent, persistent symptoms despite treatment with multiple medications, and are categorized as “difficult to treat” and “severe”… Read More »

Coronavirus live updates: WHO warns of ‘hotspots’ in Africa; Regeneron tests its potential therapy on humans

Confirmed coronavirus cases in the U.S. topped two million as the virus begins to spread more rapidly in some states that aggressively reopened such as Texas, Arizona, North Carolina and others. While health officials expected cases to rise as states reopened, the focus now is on ensuring that surges don’t boil over into uncontrolled outbreaks. … Read More »

Novartis’ new cell therapy facility could ease manufacturing squeeze for CAR-T med Kymriah

Novartis’ big push into cell and gene therapy hasn’t been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter’s production bottleneck?  Novartis last week opened its newest cell and gene therapy facility in Stein, Switzerland,… Read More »

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve

Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer. The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of… Read More »